

Title: BAYER AND CIS BIOTECH T...
Date: 11/01/2005
Location: Northfield, IL
Frequency: Monthly
Pub Number: 50B-1000

Bayer and CIS Biotech to develop serum assays for stroke

Bayer HealthCare, Diagnostics Division, and CIS Biotech have signed exclusive development and license agreements that allow the companies to collaborate on the commercialization of automated serum assays for stroke testing based on CIS Biotech's proprietary immunoassays for NMDA NR2 receptor and antibodies

Under terms of the agreements, CIS Biotech will work with Bayer to develop and commercialize the NR2 assays for use on Bayer's Advia Centaur line of automated immunoassay systems as well as future Bayer systems

The assay is currently only available for use in research settings.

Bayer HealthCare, Circle No. 227

CIS Biotech, Circle No. 228